title: In vitro penetration properties of solid lipid nanoparticles in intact and barrier-impaired skin.
abstract: Treatment of skin diseases implies application of a drug to skin with an impaired epidermal barrier, which is likely to affect the penetration profile of the drug substance as well as the carrier into the skin. To elucidate this, the effect of skin barrier damage on the penetration profile of a corticosteroid applied in solid lipid nanoparticles (SLN) composed of different lipids, varying in polarity, was studied. The studies were carried out in vitro using impaired and intact porcine ear skin, and the SLN were compared with a conventional ointment. It was shown that a significantly higher amount of corticosteroid remained in the skin, intact as well as barrier impaired, when SLN was used as a vehicle. In general, the penetration profile of the drug substance into the skin was affected by the type of lipid used in the formulation and related to lipid polarity and drug substance solubility. When formulated in SLN and applied to intact skin, the permeation of the drug substance across the skin was significantly reduced, as compared to the ointment. Altogether, in both barrier-impaired and intact skin, a higher amount of drug substance remained in the skin during application of SLN for 6, 16, and 24h, as compared to the ointment. These results emphasize the applicability of SLN to create a drug reservoir in skin, with the drug localized distinctively in the stratum corneum.
authors.affiliation: New Products, LEO Pharma A/S, Ballerup, Denmark. louise.bastholm-jensen@leo-pharma.com
authors.forename: L B
authors.initials: LB
authors.lastname: Jensen
authors.forename: K
authors.initials: K
authors.lastname: Petersson
authors.forename: H M
authors.initials: HM
authors.lastname: Nielsen
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000032:analysis / Q000737:chemistry / Q000378:metabolism; D001624:Betamethasone Valerate / Q000032:analysis / Q000737:chemistry / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D004423:Ear / Q000502:physiology; D005079:Excipients / Q000737:chemistry* / Q000378:metabolism; D008055:Lipids / Q000032:analysis / Q000737:chemistry*; D053758:Nanoparticles / Q000032:analysis / Q000737:chemistry*; D009824:Ointments / Q000737:chemistry / Q000378:metabolism; D010316:Particle Size; D010539:Permeability; D011136:Polysorbates / Q000737:chemistry / Q000378:metabolism; D012867:Skin / Q000293:injuries / Q000378:metabolism* / Q000473:pathology; D012869:Skin Absorption / Q000502:physiology; D012995:Solubility; D013501:Surface-Active Agents / Q000737:chemistry; D013552:Swine
chemical_list: D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D005079:Excipients; D008055:Lipids; D009824:Ointments; D011136:Polysorbates; D013501:Surface-Active Agents; D001624:Betamethasone Valerate